T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.11B |
| 2 |
Meta Platforms (Facebook)
META
|
+$2.59B |
| 3 |
EQT Corp
EQT
|
+$1.31B |
| 4 |
Colgate-Palmolive
CL
|
+$1.08B |
| 5 |
Adobe
ADBE
|
+$1.06B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.92B |
| 2 |
UnitedHealth
UNH
|
+$1.78B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.55B |
| 4 |
Ross Stores
ROST
|
+$1.54B |
| 5 |
ASML
ASML
|
+$1.49B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.61% |
| 2 | Healthcare | 16.91% |
| 3 | Consumer Discretionary | 11.05% |
| 4 | Financials | 10.6% |
| 5 | Communication Services | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2051
Recursion Pharmaceuticals
RXRX
$1.78B
| $574K | ﹤0.01% |
76,826
+2,033
| +3% | +$14.2K |
|
2052
Coursera
COUR
$1.53B
| $573K | ﹤0.01% |
43,976
-11,541
| -21% | -$138K |
|
2053
Virgin Galactic
SPCE
$475M
| $573K | ﹤0.01% |
7,379
+748
| +11% | +$59.2K |
|
2054
Travere Therapeutics
TVTX
$5.79B
| $571K | ﹤0.01% |
37,151
+5,861
| +19% | +$107K |
|
2055
Viridian Therapeutics
VRDN
$2.49B
| $570K | ﹤0.01% |
23,945
+1,286
| +6% | +$33K |
|
|
TBCH
2056
Turtle Beach Corp
TBCH
$230M
| $570K | ﹤0.01% |
48,884
-1,617
| -3% | -$18K |
|
2057
JELD-WEN Holding
JELD
$170M
| $568K | ﹤0.01% |
32,332
+1,297
| +4% | +$18.1K |
|
|
FSR
2058
DELISTED
Fisker Inc.
FSR
| $568K | ﹤0.01% |
100,643
+10,747
| +12% | +$62K |
|
|
PRA
2059
DELISTED
ProAssurance
PRA
| $567K | ﹤0.01% |
37,544
+1,000
| +3% | +$15.7K |
|
2060
B&G Foods
BGS
$299M
| $566K | ﹤0.01% |
40,599
+1,031
| +3% | +$14.8K |
|
2061
Dillards
DDS
$9.59B
| $566K | ﹤0.01% |
1,732
-34
| -2% | -$10.4K |
|
2062
PetMed Express
PETS
$43.4M
| $565K | ﹤0.01% |
40,908
+4,264
| +12% | +$64K |
|
2063
Shore Bancshares
SHBI
$799M
| $565K | ﹤0.01% |
48,874
+4,583
| +10% | +$56.1K |
|
|
PLL
2064
DELISTED
Piedmont Lithium
PLL
| $564K | ﹤0.01% |
9,758
+303
| +3% | +$17.3K |
|
2065
Fidelity MSCI Information Technology Index ETF
FTEC
$21.6B
| $563K | ﹤0.01% |
4,302
| – | – |
|
2066
Orthofix Medical
OFIX
$415M
| $563K | ﹤0.01% |
31,158
+459
| +1% | +$8.57K |
|
2067
Center Bancorp
CNOB
$1.81B
| $562K | ﹤0.01% |
33,845
+466
| +1% | +$7.27K |
|
2068
Sonic Automotive
SAH
$2.51B
| $562K | ﹤0.01% |
11,783
-193
| -2% | -$8.9K |
|
2069
Mercury Insurance
MCY
$5.81B
| $561K | ﹤0.01% |
18,515
+455
| +3% | +$13.9K |
|
|
PDM
2070
Piedmont Realty Trust
PDM
$1.2B
| $561K | ﹤0.01% |
77,142
+1,659
| +2% | +$11K |
|
2071
Arcturus Therapeutics
ARCT
$223M
| $553K | ﹤0.01% |
19,257
-617
| -3% | -$16.8K |
|
2072
Dorian LPG
LPG
$1.95B
| $553K | ﹤0.01% |
21,547
-21,509
| -50% | -$488K |
|
2073
Park Aerospace
PKE
$811M
| $553K | ﹤0.01% |
40,030
| – | – |
|
|
PRSU
2074
Pursuit Attractions and Hospitality Inc
PRSU
$1.29B
| $553K | ﹤0.01% |
20,538
+311
| +2% | +$6.91K |
|
|
INFN
2075
DELISTED
Infinera Corporation Common Stock
INFN
| $553K | ﹤0.01% |
114,415
+2,179
| +2% | +$12K |
|
Similar funds
T. Rowe Price Associates's Q2 2023 Portfolio in Review
As of Q2 2023, T. Rowe Price Associates held 3,044 positions worth $718B, up 7.4% from $668B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2023 filing shows 123 new, 1,636 increased, 968 reduced and 150 closed positions. Its largest new stake was Kenvue: 26,317,608 shares worth $695M. The largest sale was Microsoft, an estimated $1.92B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2023 buy was Kenvue: 26,317,608 shares worth $695M.
- T. Rowe Price Associates added most to Amazon in Q2 2023, an estimated $3.11B increase.
- T. Rowe Price Associates's biggest Q2 2023 reduction was Microsoft, cutting an estimated $1.92B.
- T. Rowe Price Associates fully exited Canadian Natural Resources in Q2 2023, selling an estimated $112M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $718B portfolio in Q2 2023.
- T. Rowe Price Associates opened 123 new positions and closed 150 in Q2 2023.
- T. Rowe Price Associates's portfolio value rose 7.4% quarter-over-quarter to $718B.
Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.